JK Biostatistics AB   Report issue

For profit Phase 3
Founded: Stockholm Sweden (1997)

Organization Overview

First Clinical Trial
2020
NCT04327505
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

JK Biostatistics AB

Active Ingredients

Drugs in Phase 3 Trials (1)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Lung Injury (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1